
    
      Forty-eight patients enrolled, not bleeding, will be randomized to receive two injections
      separated by a washout period of 3 days (t1/2 = 2.3h). Patients are centrally registered and
      randomized to receive in a 2x2 cross-over setting either a single dose of two for the
      following products: A: AryoSeven 90 µg/kg and B: NovoSeven 90 µg/kg - or - C: AryoSeven 270
      µg/kg and D: NovoSeven 270 µg/kg.

      Patients will be hospitalized at the time of study medication administration and plasma
      sampling. Before any treatment, a blood sample will be obtained in all patients for testing
      for immunogenicity.
    
  